Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Rand Sutherland, MD, MPH, will deliver a presentation on Monday, January 13, 2025, at 2:15 p.m. PT.

The presentation will be accessible via live webcast through the 'Events' tab on the 'Investors' section of Upstream Bio's website. For those unable to attend the live session, a replay will be made available on the company's website following the presentation.

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio’s CEO, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 p.m. PT.  

A live webcast of the presentation will be available under the “Events” tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation.

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

FAQ

When is Upstream Bio (UPB) presenting at the 2025 J.P. Morgan Healthcare Conference?

Upstream Bio will present at the conference on Monday, January 13, 2025, at 2:15 p.m. PT.

How can investors watch Upstream Bio's (UPB) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast available under the 'Events' tab on the 'Investors' page of Upstream Bio's website.

Will there be a replay available of Upstream Bio's (UPB) J.P. Morgan presentation?

Yes, a replay of the webcast will be posted on Upstream Bio's website following the presentation.

What is Upstream Bio's (UPB) current focus in drug development?

Upstream Bio is developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.